Current Report Filing (8-k)
June 14 2023 - 4:06PM
Edgar (US Regulatory)
0000727510
false
0000727510
2023-06-08
2023-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2023
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation) |
|
001-36435
(Commission File Number) |
|
22-2372868
(IRS Employer Identification No.) |
20 Commerce Drive (Suite
135), Cranford, New Jersey
(Address of principal executive
offices) |
|
07016
(Zip Code) |
(732) 980-4500
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
The 2023 virtual annual meeting of stockholders (the “Annual
Meeting”) of Enzon Pharmaceuticals, Inc. (the “Company”) was held on June 8, 2023. At the Annual
Meeting, the Company’s stockholders voted on the following matters as described in the Company’s proxy materials: (1) the
election of three directors, each for a one-year term expiring at the Company’s next annual meeting of stockholders and until such
director’s successor is elected and qualified, (2) the ratification of the appointment of EisnerAmper LLP as the Company’s
independent registered public accounting firm for the fiscal year ending December 31, 2023, and (3) the approval, on an advisory basis,
of the compensation of the Company’s named executive officer. A total of 55,089,122 shares of common stock were present or represented
by proxy at the Annual Meeting, representing approximately 74% of the total shares of common stock entitled to vote. As such, a quorum
was present.
The following is a brief description of each matter voted upon and
the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes
with respect to each matter. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of
1934, as amended, and there was no solicitation in opposition of management’s solicitation.
1. |
Election of Directors - The Company’s stockholders elected each of the following individuals as a director for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, as set forth below: |
Nominee |
|
Votes For |
|
|
Votes Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
Jordan Bleznick |
|
|
40,933,362 |
|
|
|
481,896 |
|
|
|
25,681 |
|
|
|
13,648,183 |
|
Jaffery (Jay) A. Firestone |
|
|
40,948,084 |
|
|
|
467,174 |
|
|
|
25,681 |
|
|
|
13,648,183 |
|
Randolph C. Read |
|
|
40,928,180 |
|
|
|
489,078 |
|
|
|
23,681 |
|
|
|
13,648,183 |
|
2. |
Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 - This proposal was approved as set forth below: |
Votes For |
|
|
Votes Against |
|
|
Abstentions |
|
54,887,457 |
|
|
|
169,364 |
|
|
|
32,301 |
|
3. |
Approval, on an advisory basis, of the compensation of the Company’s named executive officer - This proposal was approved as set forth below: |
Votes For |
|
|
Votes Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
40,481,594 |
|
|
|
834,297 |
|
|
|
125,048 |
|
|
|
13,648,183 |
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ENZON PHARMACEUTICALS, INC. |
|
(Registrant) |
Date: June 14, 2023 |
|
|
|
By: |
/s/ Richard L. Feinstein |
|
Name: |
Richard L. Feinstein |
|
Title: |
Chief Executive Officer, Chief Financial Officer and Secretary |
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Aug 2023 to Aug 2024